Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

The PIK3CA gene helps to guide the PIK3CA protein to make sure that cells in your body grow, divide, and die normally. When there is a mutation in PIK3CA, ...

The research provides a comprehensive analysis of PIK3CA mutations, ... Activated AKT phosphorylates TSC1/2 and relieves its inhibition function on mTORC1, promoting protein translation.

pik3ca The PIK3CA gene gives instructions to make a protein that’s important for many cell functions. A PIK3CA mutation isn’t inherited – you can’t pass it down to your children.

Breaking down the PIK3CA protein. The new drug, inavolisib works by blocking the activity of the PIK3CA protein. However, it also has a second mode of action which triggers the breakdown of the ...

PIK3CA-related overgrowth spectrum (PROS) is a rare genetic condition that affects children in many ways. Read more about the types of PROS, their symptoms, and treatment options.

Randee’s cancer had metastasized. When her doctor tested her for the PIK3CA gene mutation, she was able to make informed decisions about her disease journey.

Protein-protein interaction network of the 53 potential targets for treating breast cancer. ... The more GADM they used, the more it suppressed PIK3CA protein in breast cancer cells, ...

The INAVO120 study reveals that the three-drug therapy inavolisib, palbociclib and fulvestrant significantly delays cancer progression in PIK3CA-mutated breast cancer. The therapy has received FDA ...